Does stopping renin-angiotensin system inhibitors after hyperkalemia affect the risk of adverse outcomes?
Stopping RASi after hyperkalemia is associated with a trade-off between reduced recurrent hyperkalemia and increased risk of death and cardiovascular events.
These findings suggest that stopping RASi after hyperkalemia may be associated with a lower risk of recurrence of hyperkalemia, but higher risk of death and cardiovascular events.
Xu et al. (Mon,) studied this question.